3 Biotechnology Stocks to Buy Now

by Portfolio Grader | December 5, 2012 2:00 pm

This week, three Biotechnology stocks are improving their overall ratings on Portfolio Grader[1]. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

YM BioSciences (AMEX:YMI[2]) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. YM BioSciences is a drug development company, engages in advancing three clinical-stage hematology and cancer-related products. In Portfolio Grader’s specific subcategories of Earnings Revisions and Sales Growth, YMI also gets A’s. For more information, get Portfolio Grader’s complete analysis of YMI stock[3].

Keryx Biopharmaceuticals (NASDAQ:KERX[4]) shows solid improvement this week. The company’s rating rises from a C to a B. Keryx Biopharmaceuticals focuses on developing and commercializing pharmaceuticals for the treatment of cancer and renal disease. The stock price has risen 26.3% over the past month, better than the 0.1% the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of KERX stock[5].

Synergy Pharmaceuticals (NASDAQ:SGYP[6]) earns a B this week, jumping up from last week’s grade of C. Synergy Pharmaceuticals is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. Wall Street has pushed the stock higher by 56% over the past month. For more information, get Portfolio Grader’s complete analysis of SGYP stock[7].

Louis Navellier’s proprietary Portfolio Grader[8] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[9].

Source URL: https://investorplace.com/2012/12/3-biotechnology-stocks-to-buy-now-ymi-kerx-sgyp/

---